Live feed08:00:00·385dPRReleasevia QuantisnowProtagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia VeraByQuantisnow·Wall Street's wire, on your screen.PTGX· Protagonist Therapeutics Inc.TAK· Takeda Pharmaceutical Company LimitedHealth Care
